Although mixed lineage kinase domain-like protein(MLKL)is widely recognized as a critical effector in the necroptotic signaling pathway,MLKL plays broader regulatory roles beyond programmed necroptosis.Notably,Xuan Yu...Although mixed lineage kinase domain-like protein(MLKL)is widely recognized as a critical effector in the necroptotic signaling pathway,MLKL plays broader regulatory roles beyond programmed necroptosis.Notably,Xuan Yuan et al demonstrated that CPD4,an ATP-binding pocket inhibitor of MLKL,significantly reduces liver inflammation and improves liver function by inhibiting NF-κB signaling,suggesting its use as a potential therapeutic candidate for alcoholic liver disease.However,the pharmacokinetic properties and long-term toxicity of CPD4 require further evaluation.Moreover,a single therapeutic strategy targeting MLKL may not be sufficient.Future studies should focus on the precise regulation of MLKL and develop combination therapies to achieve dual intervention of inflammatory and cell death pathways.This paper provides an important theoretical foundation for translational research on MLKL-targeted therapy.However,its clinical translation requires overcoming existing limitations and further elucidating the regulatory network of MLKL in complex microenvironments.展开更多
Objective:To assess the efficacy of chlorophyl lderivative（CPD4）-Photodynamic therapy（PDT）in preventing postoperative recurrence of the in filtrativecancer of the urinary bladder-Methods:32 patients were treated w...Objective:To assess the efficacy of chlorophyl lderivative（CPD4）-Photodynamic therapy（PDT）in preventing postoperative recurrence of the in filtrativecancer of the urinary bladder-Methods:32 patients were treated with CPD4-PDT postoperationally to prevent therecurrence of can cerall of which being followedup.Results:There currenc erate was42.1%inT2 tumors and 69.2%inT3 tumors（P＜0.05）,and the survival period without tumor has been 19.8±14.8months in T2 tumors,and 22.67±19.72months in T3 tumors（P＞0.05）.There was verysignificant difference inrecurrent rate between grade I and gradeⅡ、Ⅲpatients（0%and66.7%,P<0.001）.ConcIusion:CPD4-PDT is a safe and effectiv emeasureto prevent the recurrence in infiltrative bladder cancer after operation.展开更多
文摘Although mixed lineage kinase domain-like protein(MLKL)is widely recognized as a critical effector in the necroptotic signaling pathway,MLKL plays broader regulatory roles beyond programmed necroptosis.Notably,Xuan Yuan et al demonstrated that CPD4,an ATP-binding pocket inhibitor of MLKL,significantly reduces liver inflammation and improves liver function by inhibiting NF-κB signaling,suggesting its use as a potential therapeutic candidate for alcoholic liver disease.However,the pharmacokinetic properties and long-term toxicity of CPD4 require further evaluation.Moreover,a single therapeutic strategy targeting MLKL may not be sufficient.Future studies should focus on the precise regulation of MLKL and develop combination therapies to achieve dual intervention of inflammatory and cell death pathways.This paper provides an important theoretical foundation for translational research on MLKL-targeted therapy.However,its clinical translation requires overcoming existing limitations and further elucidating the regulatory network of MLKL in complex microenvironments.
文摘Objective:To assess the efficacy of chlorophyl lderivative（CPD4）-Photodynamic therapy（PDT）in preventing postoperative recurrence of the in filtrativecancer of the urinary bladder-Methods:32 patients were treated with CPD4-PDT postoperationally to prevent therecurrence of can cerall of which being followedup.Results:There currenc erate was42.1%inT2 tumors and 69.2%inT3 tumors（P＜0.05）,and the survival period without tumor has been 19.8±14.8months in T2 tumors,and 22.67±19.72months in T3 tumors（P＞0.05）.There was verysignificant difference inrecurrent rate between grade I and gradeⅡ、Ⅲpatients（0%and66.7%,P<0.001）.ConcIusion:CPD4-PDT is a safe and effectiv emeasureto prevent the recurrence in infiltrative bladder cancer after operation.
